Background:
Many hematologic neoplasms are characterized by mutations in multiple genes, and their presence can provide diagnostic, prognostic and therapeutic information. The PAN-HEME panel utilizes next-generation sequencing on DNA and RNA to detect 195 gene variants that are commonly found in myeloid and lymphoid neoplasms, such as acute myeloid leukemias (AML), acute lymphoblastic leukemias (ALL) including Ph-like ALL, myelodysplasias (MDS), myeloproliferative disorders (MPN), and chronic lymphocytic leukemias (CLL).
Note: This panel will replace the Myeloid-75 panel assay.
Methodology and reporting:
Next generation sequencing is performed on DNA and RNA extracted from whole blood or bone marrow. This is a targeted assay that covers 195 variants including single nucleotide substitutions, small insertions and deletions, gene fusions and copy number variations commonly associated with myelo-lymphoid neoplasms (see link for list). Variants are reported according to HGVS nomenclature and classified as per the AMP classification system into tiers IA, IB, IIC, IID, III and IV. The panel has a sensitivity of ~5% for each mutant allele.
Effective date: August 17, 2021
Specimen: 4.0 mL whole blood or 2.0 mL bone marrow in EDTA (lavender) tube
Test methodology: Next Generation Sequencing
Test code: PANHEM
CPT code: 81455
Turnaround time (TAT):
STAT: N/A
Routine: 10-14 days
Set-up days: Once a week
Stability:
Ambient: Unacceptable
Refrigerated: up to 3 days from collection date (bone marrow or whole blood)
Frozen: Unacceptable
Rejection criteria:
Specimens that exceed stated stability, gross hemolysis, specimens submitted in leaking containers, unlabeled/mislabeled/mismatched specimens
View the variant list ›
A summary of all tests offered by our laboratory services can be found here: http://www.pathology.uci.edu/services/index.asp
Sincerely,
Jeff Chan, MD, PhD
Director
Diagnostic Molecular Pathology Laboratory
Edwin S. Monuki, MD, PhD
Chair
Department of Pathology & Laboratory Medicine
|
